Paxlovid Works much WORSE in the Vaccinated and NOT AT ALL in the younger ones!
A new study from Israel tried
to assess the real-world benefits of Paxlovid and tried (clumsily) to separate
patients by “vaccination status”.
https://www.researchsquare.com/article/rs-1705061/v1
All patients were classified into one of two categories according to
their Covid-19 immune status; participants with no prior immunity (unvaccinated or vaccinated with
only one mRNA vaccine dose and also with no previous documented SARS-CoV-2
infection) or participants that had already acquired prior immunity (vaccine-induced,
infection-induced, or hybrid).
You can see why I think that this is a clumsy way to stratify patients:
in my own mind, there is a huge difference between a no-dose patient who never
received any Pfizer vaccine, and a one-dose patient who received one dose, and
possibly was injured by it and declined subsequent doses. Unfortunately, we are
stuck with the way this study stratifies the patients into immunity-free and
immune subgroups.
For simplicity, I will still refer to them as vaccinated vs
unvaccinated, but be mindful of the above caveat regarding the study’s
stratification So, without further complaining, let’s go on to the results.
What is it showing? Look at the first underlined line, “no prior
immunity”. You will see that for people with “no prior immunity”, Paxlovid works fairly well.
For example, for younger 40-64yo “no prior immunity” patients, Paxlovid-treated
persons have only 0.21 times the risk of untreated patients. For the older
over-65 years old group, the risk for Paxlovid-treated patients is only 14% of
the no-Paxlovid group. For the unvaccinated (no-immunity, see discussion above)
Paxlovid works a little worse than in the Pfizer-sponsored EPIC-HR trial, but
still decently.
The shocker lies in the vaccinated group! Paxlovid does NOT work at all — and shows INFERIOR RESULTS — in the
younger 40-64 unvaccinated subgroup. In fact, the small statistical sample
shows that the risk of severe outcomes in the Paxlovid group is HIGHER than in
the no-Paxlovid group (1.18). The sample is relatively small, but you can see
that for younger
vaccinated persons, Paxlovid is at best useless, and at worst, harmful.
For older vaccinated people, Paxlovid does have some efficiency, but
much more modest than advertised, and instead of the promised 89%
effectiveness, those older vaccinated people only get 60% effectiveness
(equivalent to the 40% hazard ratio).
The picture is
telling:
In fact, the late rise in the 40-64 treatment group hints at the
“Paxlovid Rebound”, which I brought up early on April 13, before any data was available, based just on a bunch of Reddit posts.
This is Why Pfizer did not Want to Include the Vaccinated
Had Pfizer included vaccinated people, the results would look something
like what is underlined with BLUE line:
The results with vaccinated people included would show utter lack of
effectiveness in the younger group, statistically indistinguishable from a
placebo. It would show very modest effectiveness (67%, equivalent to HR of
0.33) in the older group.
Such a joke medication would probably be still approved by the FDA —
they approve everything that Pfizer asks for — but the outcry from the public
would probably embarrass everyone.
So, what did Pfizer do? They wisely kicked vaccinated people out of the EPIC-SR trial so that their medication would artificially look good.
What About Children?
This section of my article is by necessity more speculative. What
Israeli data shows is that the younger the patients get, the more useless — if
not outright harmful — Paxlovid gets for them.
What if this gets even worse for even younger patients? What if Paxlovid
is actually harmful to children or young adults? It was never tested on children at all! Despite an absolute lack of clinical trial data on Paxlovid in
children, the FDA recklessly approved it anyway for 12-18-year-old kids.
I am praying that no children will be harmed by Paxlovid — and if they
get harmed, EUA prevents any legal liability.
Would you give Paxlovid to your children? Let us know in the comments!
A few comments …
 |
Writes The Dynamics of Societal Collap… ·5 hr ago·edited 5 hr agoPinned The HK study similarly shows it doesn't do
much... It has both vaccinated and unvaccinated patients in the Paxlovid
cohort. Molnupiravir may make things worse, though it lacks statistical
significance. https://jestre.substack.com/p/new-study-obliterates-paxlovid-and?s=w Funny they gave both drugs to the
vaccinated despite no trials in the vaccinated. Pretty unethical
imo |
 |
5 hr agoAuthor I am going to pin your comment on top, it is perfectly on target and I
hope people check your article out |
 |
I just did & subscribed. I had nearly forgotten about
Molnupiravir. |
 |
Writes The Dynamics of Societal Collap… ·5 hr ago Liked by Igor Chudov Harmaceuticals |
